AveXis (AVXS): Raising PT After Gene Editing Summit Points To Improvements - Jefferies

October 12, 2016 9:16 AM EDT
Get Alerts AVXS Hot Sheet
Price: $46.00 -1.31%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 26 | Down: 29 | New: 38
Trade AVXS Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of AveXis (NASDAQ: AVXS) and increased his price target to $58 from $50 after the company presented at the Jefferies Gene Editing Summit.

Management reiterated their impressive motor milestone data, initially presented at World Muscle however, this was taken one step further as the company disclosed that the patient has come off of permanent ventilation and is recovering well from surgery.

The analyst updated the model for a 30% risk adjustment (lower) for AVXS-101 in SMA Type 1 resulting in the higher price target.

For an analyst ratings summary and ratings history on AveXis click here. For more ratings news on AveXis click here.

Shares of AveXis closed at $48.97 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Management Comments

Related Entities

Jefferies & Co, S1

Add Your Comment